Organovo reports Q3 EPS (7c) vs. (20c) a year ago Reports Q3 revenue $135K, one estimate $180K. The company said its decrease in revenue from prior year levels reflects declining activity under an existing collaborative agreement and the conclusion of a previous collaborative research agreement during the quarter, partially offset by increasing revenue contributions from three recently signed agreements. Organovo is a development stage company, and does not expect product-based revenue until the commercial release of its liver toxicity assay product, currently planned to be before the end of November.
News For ONVO From The Last 14 Days
Check below for free stories on ONVO the last two weeks.